AstraZeneca PLC AZNCF
News
AstraZeneca to pay up to $2 billion to license cardiovascular drug
AstraZeneca's Experimental Cancer Drug Misses Target in Pivotal Trial — Update
AstraZeneca's Breast Cancer Drug Missed Targets in Phase Three Trial
MedImmune Receives FDA Approval for Self-Administered Flu Vaccine
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
AstraZeneca Employees Detained in China Over Alleged Data, Drug-Import Violations — Update
AstraZeneca Employees Detained in China Over Data and Drug-Import Scrutiny
5 things you need to know about COVID, flu and RSV vaccines this fall
AstraZeneca's Imfinzi Wins FDA Priority Review to Treat Limited-Stage Small Cell Lung Cancer
AstraZeneca's U.K. Vaccine Facility at Risk Due to Government Aid Cuts, FT Reports
England's NHS Watchdog Denies Access to AstraZeneca's Breast Cancer Drug
AstraZeneca Raises Guidance After Results Beat Market Expectations — Update
AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca
AstraZeneca's Imfinzi Gets Positive Results in Bladder Cancer Trial
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals
AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer
AstraZeneca's Farxiga Approved For Treating Pediatric Type-2 Diabetes in U.S.
AstraZeneca started at buy at Goldman, which rates GSK a neutral